Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 13

1.

Proteomic profiling of the infective trophozoite stage of Acanthamoeba polyphaga.

Caumo KS, Monteiro KM, Ott TR, Maschio VJ, Wagner G, Ferreira HB, Rott MB.

Acta Trop. 2014 Dec;140:166-72. doi: 10.1016/j.actatropica.2014.08.009. Epub 2014 Aug 18.

2.

AC-260584, an orally bioavailable M(1) muscarinic receptor allosteric agonist, improves cognitive performance in an animal model.

Bradley SR, Lameh J, Ohrmund L, Son T, Bajpai A, Nguyen D, Friberg M, Burstein ES, Spalding TA, Ott TR, Schiffer HH, Tabatabaei A, McFarland K, Davis RE, Bonhaus DW.

Neuropharmacology. 2010 Feb;58(2):365-73. doi: 10.1016/j.neuropharm.2009.10.003. Epub 2009 Oct 14.

PMID:
19835892
3.

Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonists.

Pettersson H, B├╝low A, Ek F, Jensen J, Ottesen LK, Fejzic A, Ma JN, Del Tredici AL, Currier EA, Gardell LR, Tabatabaei A, Craig D, McFarland K, Ott TR, Piu F, Burstein ES, Olsson R.

J Med Chem. 2009 Apr 9;52(7):1975-82. doi: 10.1021/jm801534c.

PMID:
19338356
4.

Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation.

Spalding TA, Ma JN, Ott TR, Friberg M, Bajpai A, Bradley SR, Davis RE, Brann MR, Burstein ES.

Mol Pharmacol. 2006 Dec;70(6):1974-83. Epub 2006 Sep 7.

PMID:
16959945
5.

The N-terminal domain of CCL21 reconstitutes high affinity binding, G protein activation, and chemotactic activity, to the C-terminal domain of CCL19.

Ott TR, Lio FM, Olshefski D, Liu XJ, Ling N, Struthers RS.

Biochem Biophys Res Commun. 2006 Sep 29;348(3):1089-93. Epub 2006 Aug 4.

PMID:
16904643
6.

Pharmacological and behavioral profile of N-(4-fluorophenylmethyl)-N-(1-methylpiperidin-4-yl)-N'-(4-(2-methylpropyloxy)phenylmethyl) carbamide (2R,3R)-dihydroxybutanedioate (2:1) (ACP-103), a novel 5-hydroxytryptamine(2A) receptor inverse agonist.

Vanover KE, Weiner DM, Makhay M, Veinbergs I, Gardell LR, Lameh J, Del Tredici AL, Piu F, Schiffer HH, Ott TR, Burstein ES, Uldam AK, Thygesen MB, Schlienger N, Andersson CM, Son TY, Harvey SC, Powell SB, Geyer MA, Tolf BR, Brann MR, Davis RE.

J Pharmacol Exp Ther. 2006 May;317(2):910-8. Epub 2006 Feb 9.

PMID:
16469866
7.

Characterization of the Mas-related gene family: structural and functional conservation of human and rhesus MrgX receptors.

Burstein ES, Ott TR, Feddock M, Ma JN, Fuhs S, Wong S, Schiffer HH, Brann MR, Nash NR.

Br J Pharmacol. 2006 Jan;147(1):73-82.

8.

A high-throughput chemotaxis assay for pharmacological characterization of chemokine receptors: Utilization of U937 monocytic cells.

Ott TR, Pahuja A, Lio FM, Mistry MS, Gross M, Hudson SC, Wade WS, Simpson PB, Struthers RS, Alleva DG.

J Pharmacol Toxicol Methods. 2005 Mar-Apr;51(2):105-14. Epub 2004 Nov 5.

PMID:
15767203
9.

Identification of CC chemokine receptor 7 residues important for receptor activation.

Ott TR, Pahuja A, Nickolls SA, Alleva DG, Struthers RS.

J Biol Chem. 2004 Oct 8;279(41):42383-92. Epub 2004 Jul 28.

10.

Determinants of high-affinity binding and receptor activation in the N-terminus of CCL-19 (MIP-3 beta).

Ott TR, Lio FM, Olshefski D, Liu XJ, Struthers RS, Ling N.

Biochemistry. 2004 Mar 30;43(12):3670-8.

PMID:
15035637
11.
12.

Two mutations in extracellular loop 2 of the human GnRH receptor convert an antagonist to an agonist.

Ott TR, Troskie BE, Roeske RW, Illing N, Flanagan CA, Millar RP.

Mol Endocrinol. 2002 May;16(5):1079-88.

PMID:
11981042
13.

A chicken gonadotropin-releasing hormone receptor that confers agonist activity to mammalian antagonists. Identification of D-Lys(6) in the ligand and extracellular loop two of the receptor as determinants.

Sun YM, Flanagan CA, Illing N, Ott TR, Sellar R, Fromme BJ, Hapgood J, Sharp P, Sealfon SC, Millar RP.

J Biol Chem. 2001 Mar 16;276(11):7754-61. Epub 2000 Dec 8.

Supplemental Content

Support Center